Therapeutics of Alzheimer's disease: Past, present and future
Alzheimer's disease (AD) is the most common cause of dementia worldwide. The etiology is
multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential …
multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential …
Therapeutics of neurotransmitters in Alzheimer's disease
R Kandimalla, PH Reddy - Journal of Alzheimer's Disease, 2017 - content.iospress.com
Alzheimer's disease (AD) is a progressive neurodegenerative disease, characterized by the
loss of memory, multiple cognitive impairments and changes in the personality and …
loss of memory, multiple cognitive impairments and changes in the personality and …
Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic …
AL Pehrson, C Sanchez - Drug design, development and therapy, 2015 - Taylor & Francis
Evidence suggesting that central nervous system γ-aminobutyric acid (GABA)
concentrations are reduced in patients with major depressive disorder (MDD) has been …
concentrations are reduced in patients with major depressive disorder (MDD) has been …
Serotonergic innervation of the amygdala: targets, receptors, and implications for stress and anxiety
The amygdala is a core component of neural circuits that mediate processing of emotional,
particularly anxiety and fear-related stimuli across species. In addition, the nuclear complex …
particularly anxiety and fear-related stimuli across species. In addition, the nuclear complex …
[HTML][HTML] A pilot study on the effect of lactoferrin on Alzheimer's disease pathological sequelae: Impact of the p-Akt/PTEN pathway
WA Mohamed, RM Salama, MF Schaalan - Biomedicine & …, 2019 - Elsevier
Alzheimer's disease (AD) is one of the most common neurodegenerative diseases in which
the phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)/protein kinase B (PKB or Akt) …
the phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)/protein kinase B (PKB or Akt) …
Cyto-and receptor architectonic mapping of the human brain
N Palomero-Gallagher, K Zilles - Handbook of clinical neurology, 2018 - Elsevier
Mapping of the human brain is more than the generation of an atlas-based parcellation of
brain regions using histologic or histochemical criteria. It is the attempt to provide a …
brain regions using histologic or histochemical criteria. It is the attempt to provide a …
5-HT6 receptor antagonists: potential efficacy for the treatment of cognitive impairment in schizophrenia
N MWJ de Bruin, CG Kruse - Current Pharmaceutical Design, 2015 - ingentaconnect.com
5-hydroxytryptamine6 receptor (5-HT6R) antagonists have shown efficacy in animal models
for cognitive impairment in multiple cognitive domains relevant for schizophrenia …
for cognitive impairment in multiple cognitive domains relevant for schizophrenia …
Pet-1 switches transcriptional targets postnatally to regulate maturation of serotonin neuron excitability
SC Wyler, WC Spencer, NH Green… - Journal of …, 2016 - Soc Neuroscience
Newborn neurons enter an extended maturation stage, during which they acquire excitability
characteristics crucial for development of presynaptic and postsynaptic connectivity. In …
characteristics crucial for development of presynaptic and postsynaptic connectivity. In …
Tryptophan depletion promotes habitual over goal-directed control of appetitive responding in humans
Background: Optimal behavioral performance results from a balance between goal-directed
and habitual systems of behavioral control, which are modulated by ascending …
and habitual systems of behavioral control, which are modulated by ascending …
Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs
MJ Millan, A Dekeyne, A Gobert, M Brocco… - …, 2020 - Elsevier
To date, there are no interventions that impede the inexorable progression of Alzheimer's
disease (AD), and currently-available drugs cholinesterase (AChE) inhibitors and the N …
disease (AD), and currently-available drugs cholinesterase (AChE) inhibitors and the N …